Glioblastoma multiforme (GBM) is the most common type of brain tumor and it is considered as one of the most aggressive malignancies (1.5 years of survival rate).
Objective:
Determine the antitumor potential of bismuth lipophilic nanoparticles (BisBAL NP) on a human glioblastoma cell-line.
Methods:
BisBAL NP were characterized by scanning electron microscopy (SEM). BisBAL NP entry and intracellular distribution on U-87 MG cells were observed by transmission electron microscopy (TEM). The effect of BisBAL NP on tumor cells was evaluated by MTT assay (IC50 value), Calcein AM staining, Live/dead assay, apoptosis quantification, and comet assay.
Results:
BisBAL NP-induced cytotoxicity more efficient than temozolomide (TMZ). The IC50 value of BisBAL NP was 12.7 µM. For the first time, direct interaction between BisBAL NP and plasmatic U-87 MG cell membrane was obtained by TEM. Calcein AM assay revealed loss of permeability of tumor cells after 24 h-exposure to 25 µM of BisBAL NP. 25 µM of BisBAL induced 48.5% of apoptosis, while 50 µM of BisBAL induced a higher rate of apoptosis 77.2%.
Conclusion:
BisBAL NP inhibited U-87 MG cell growth through membrane attack and loss membrane permeability, apoptosis induction and later promoting genotoxicity among tumor cells.
KoshyMVillanoJLDolecekTA, et al.Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neuro-Oncol2012; 107: 207–212.
2.
GrochansSCybulskaAMSimińskaD, et al.Epidemiology of glioblastoma multiforme-literature review. Cancers (Basel)2022; 14: 2412.
3.
Fabbro-PerayPZouaouiSDarlixA, et al.Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neuro-Oncol2019; 142: 91–101.
4.
LouisDNPerryAReifenbergerG, et al.The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol2016; 131: 803–820.
5.
CruzJVRBatistaCAfonsoBH, et al.Obstacles to glioblastoma treatment two decades after temozolomide. Cancers2022; 14: 3203.
6.
CzerniawskaA. Experimental investigations on the penetration of 198Au from nasal mucous membrane into cerebrospinal fluid. Acta Otolaryngol1970; 70: 58–61.
7.
NeganovaMEAleksandrovaYRSukochevaOA, et al.Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Semin Cancer Biol2022; 86: 805–833.
8.
HsingMTHsuHTChangCH, et al.Improved delivery performance of n-butylidenephthalide-polyethylene glycol-gold nanoparticles efficient for enhanced anti-cancer activity in brain tumor. Cells2022; 11: 2172.
9.
KabirSRIslamFAsaduzzamanAKM. Biogenic silver/silver chloride nanoparticles inhibit human cancer cells proliferation in vitro and Ehrlich ascites carcinoma cells growth in vivo. Sci Rep2022; 12: 8909.
10.
StavropoulouAPTheodosiouMSakellisE, et al.Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma. Colloids Surf B: Biointerfaces2022; 214: 112463.
11.
ChenHWenJ. Iron oxide nanoparticles loaded with paclitaxel inhibits glioblastoma by enhancing autophagy-dependent ferroptosis pathway. Eur J Pharmacol2022; 921: 174860.
12.
Cabral-RomeroCSolís-SotoJMSánchez-PérezY, et al.Antitumor activity of a hydrogel loaded with lipophilic bismuth nanoparticles on cervical, prostate, and colon human cancer cells. Anti-cancer Drugs2020; 31: 251–259.
13.
Hernandez-DelgadilloRGarcía-CuéllarCMSánchez-PérezY, et al.In vitro evaluation of the antitumor effect of bismuth lipophilic nanoparticles (BisBAL NPs) on breast cancer cells. Int J Nanomed2018; 13: 6089–6097.
14.
BadrigilanSHeydarpanahiFChoupaniJ, et al.A review on the biodistribution, pharmacokinetics and toxicity of bismuth-based nanomaterials. Int J Nanomed2020; 15: 7079–7096.
15.
BadireddyARHernandez-DelgadilloRSánchez-NájeraRI, et al.Synthesis and characterization of lipophilic bismuth dimercaptopropanol nanoparticles and their effects on oral microorganisms growth and biofilm formation. J Nanopart Res2014; 16: 2456.
16.
MaszczykMBanachKKarkoszkaM, et al.Chemosensitization of U-87 MG glioblastoma cells by neobavaisoflavone towards doxorubicin and etoposide. Int J Mol Sci2022; 23: 5621.
17.
WangRLiuTChenJ, et al.Paradol induces cell cycle arrest and apoptosis in glioblastoma cells. Nutr Cancer2022; 74: 3007–3014.
18.
WangCYuMZhangW. Neoantigen discovery and applications in glioblastoma: an immunotherapy perspective. Cancer Lett2022; 550: 215945.
19.
Cruz Da SilvaEMercierMCEtienne-SelloumN, et al.A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers2021; 13: 1795.
20.
El-KhayatSMArafatWO. Therapeutic strategies of recurrent glioblastoma and its molecular pathways ‘Lock up the beast’. Ecancermedicalscience2021; 15: 1176.
21.
SandbhorPGodaJMohantyB, et al.Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model. Drug Deliv Transl Res2022; 13: 608–626.
22.
MaoXCalero-PérezPMontpeyóD, et al.Intranasal administration of catechol-based Pt(IV) coordination polymer nanoparticles for glioblastoma therapy. Nanomaterials2022; 12: 1221.
23.
WangSYuYWangA, et al.Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration. Front Pharmacol2022; 13: 965789.
24.
RhamanMMIslamMRAkashS, et al.Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: at a glance. Front Cell Dev Biol2022; 10: 989471.
25.
ChirivìMBearziCRosaP, et al.Biomimetic keratin-coated gold nanoparticles for photo-thermal therapy in a 3D bioprinted glioblastoma tumor model. Int J Mol Sci2022; 23: 9528.
26.
TsymbalSAMoiseevaAAAgadzhanianNA, et al.Copper-containing nanoparticles and organic complexes: metal reduction triggers rapid cell death via oxidative burst. Int J Mol Sci2021; 22: 11065.
27.
HasanSKaralMASAkterS, et al.Influence of sugar concentration on the vesicle compactness, deformation and membrane poration induced by anionic nanoparticles. PLoS One2022; 17: e0275478.
28.
Contreras-OchoaCOLópez-ArellanoMERoblero-BartolonG, et al.Molecular mechanisms of cell death induced in glioblastoma by experimental and antineoplastic drugs: new and old drugs induce apoptosis in glioblastoma. Hum Exp Toxicol2020; 39: 464–476.
29.
SukochevaOALiuJNeganovaME, et al.Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers. Semin Cancer Biol2022; 86: 358–375.
30.
MikušováVMikušP. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci2021; 22: 9652.
31.
NikezićAVVBondžićAMVasićVM. Drug delivery systems based on nanoparticles and related nanostructures. Eur J Pharm Sci2020; 151: 105412.
32.
WuZYShenJMLangH, et al.Ph/enzyme dual sensitive and nucleus-targeting dendrimer nanoparticles to enhance the antitumour activity of doxorubicin. Pharm Dev Technol2022; 27: 357–371.
33.
JiangWChenLGuoX, et al.Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy. Theranostics2022; 12: 2987–3006.
